Diligence memo · auto-generated · as of July 2, 2026
Biosignia Inc
Biosignia Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Biosignia Inc operates in Biotechnology, based in Durham.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biosignia Inc has raised $329K in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $329K on 2012-06-28.
Most recent recorded round closed around 2012-06-28.
Valuation (modeled)modeled
Provath models Biosignia Inc at approximately $18M (range $175K–$206M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.93× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era. Within the normal band (93% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 14.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 8% of Biotechnology peers (4293 compared).
Modeled value ranks above 27% of those peers.
Closest niche peers: Hygeia Therapeutics, Inc., Act Biotech Inc, Ikonopedia, LLC, Iquum Inc, Koronis Pharma, Inc..
Peoplefiled
11 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.